CLINICAL_TRIALS
trial_result
· 2021-02-16
Clinical Trial Update: Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension [Phase 3]
Summary
Phase 3 clinical trial results for nepafenac 0.3% ophthalmic suspension in cataract showed completed status with results posted in 2021.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Actavis Inc. | Conditions: Cataract | Phase 3 | Status: COMPLETED | Results posted: 2021-02-16